Newer drug-eluting stents reduce restenosis by 38%, thrombosis by half

Newer is better when it comes to drug-eluting stents, according to a report from the Swedish Coronary Angiography and Angioplasty Registry. Newer models are associated with a 38% lower risk of restenosis and a 50% lower risk of stent thrombosis compared with old-school drug-eluting stents. Among the reasons are improved stent designs with thinner struts and more biocompatible polymers that may have an important impact on drug elution, the group says.

Using a national registry, the study evaluated the long-term outcome in all patients who underwent stent implantation with bare-metal stents, "older generation" drug-eluting stents, and "new generation" drug-eluting stents in Sweden.

The group says more studies are needed to determine what component of the new drug-eluting stents is involved in the decrease in thrombosis or restenosis--the polymer, the stent alloy or the eluting-drug.

- read the release from the European Society of Cardiology

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.